Keywords: Optima Pharma, Astellas, Dificid, Fidaxomicin, Clostridium difficile, Japan

Optimer Pharma could earn $90 million from new Astellas deal

Article | 30 March 2012

Print This

US firm Optimer Pharmaceuticals (Nasdaq: OPTR) has entered into a second deal with Japanese drug major Astellas Pharma (TOY: 4503) for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in